Law360, New York (March 17, 2009, 12:00 AM ET) -- Biotechnology company Genzyme Corp. has filed its second patent infringement lawsuit this month to block a generic version of the drug Renagel, this time targeting California-based generics maker Impax Laboratories Inc.
Genzyme filed the lawsuit Monday in the U.S. District Court for the District of Maryland, claiming that Impax’s proposed generic sevelamer hydrochloride tablets would infringe U.S. Patent Number 5,667,775.
Cambridge, Mass.-based Genzyme fired off the lawsuit shortly after receiving a notification letter on Jan. 27 from Impax alerting the plaintiff that it had filed an...
Genzyme Hits Impax With IP Suit Over Renagel ANDA
To view the full article, take a free trial now.
